ArticleJournal of cellular and molecular medicine2023

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

Britta Majchrzak-Stiller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.